SCHEMBL22797771

SCHEMBL22797771

Cc1cc(C(=O)NCCOc2ncc(C(F)(F)F)cc2Cl)cc(NC(=O)C2CC2)n1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.77
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ABL1 P00519 2/20 0.41
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 1/20 0.40
TYK2 P29597 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
PHGDH O43175 2/20 0.38
RHOC P08134 1/20 0.38
RHOA P61586 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
NPY5R Q15761 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22798237 0.90 SCN9A (0.79) SCN9AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL22798304 0.89 SCN9A (0.82) SCN9AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL30450216 0.89 SCN9A (0.82) SCN9AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL22798213 0.87 SCN9A (1.00) SCN9AKMT2ALMNASMN1; SMN2MRGPRX4
SCHEMBL30449602 0.87 SCN9A (0.78) SCN9AKMT2ALMNASMN1; SMN2MRGPRX4
SCHEMBL20595204 0.87 SCN9A (0.78) SCN9AKMT2ALMNASMN1; SMN2MRGPRX4
SCHEMBL23926187 0.86 SCN9A (0.62) SCN9AKMT2AMEN1ABL1LMNA
SCHEMBL22798432 0.86 SCN9A (0.62) SCN9AKMT2AMEN1ABL1LMNA
SCHEMBL22798282 0.86 SCN9A (0.57) SCN9AKMT2AMEN1LMNASMN1; SMN2
SCHEMBL22809512 0.86 SCN9A (0.57) SCN9AABL1TYK2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885KMT2A 1799/4885MEN1 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.